Results 311 to 320 of about 485,392 (348)

Navigating heart failure: a plain-language summary to empower people with heart failure. [PDF]

Heart Fail Rev
Code J, Sauer AJ, Mentz RJ, Monroe RE.
europepmc   +1 more source

Plain language summary of publication: Neurexan comprehensively mitigates stress-induced changes in heart rate variability and brain activity

Stephan Duller
openalex   +1 more source

A real-world study of tafamidis in people with transthyretin amyloid cardiomyopathy (ATTR-CM) with heart and nerve symptoms: a plain language summary. [PDF]

Future Cardiol
Wixner J, Dispenzieri A, Amass L, Carlsson M, Riley S, Powers E, Kelly JW.   +6 more
europepmc   +1 more source

Plain Language Summary of the Scientific opinion on welfare of animals kept for fur production. [PDF]

EFSA J
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

A plain language summary of NALIRIFOX compared with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer (NAPOLI 3)

Future Oncology
Plain Language Summary What is this summary about? This is a summary of a clinical study called NAPOLI 3. The NAPOLI 3 study included 770 patients with a type of pancreatic cancer called pancreatic ductal adenocarcinoma(PDAC).
Z. Wainberg, D. Melisi, T. Macarulla, R. P. Cid, S. Chandana, C. De, La Fouchardière, A. Dean, I. Kiss, Woo Jin, Lee, T. Goetze, E. Cutsem, Scott Paulson, Tanios B. Bekaii-Saab, Shubham Pant, R. Hubner, Zhimin Xiao, Huanyu Chen, Fawzi Benzaghou, E. O’Reilly   +20 more
semanticscholar   +1 more source

Treatment with vutrisiran in people with transthyretin amyloidosis with cardiomyopathy: a plain language summary

Future Cardiology
Plain Language Summary What is this summary about? This summary explains the results of the HELIOS-B study that assessed vutrisiran treatment in transthyretin amyloidosis with cardiomyopathy (ATTR-CM).
M. Fontana, Julian D. Gillmore, R. Witteles, Ben Laryea, M. Dworkin, Ann Payne, Fran M Kochman, S. Eraly, Mathew S. Maurer   +8 more
semanticscholar   +1 more source

Part A of the LILAC study of litifilimab for systemic lupus erythematosus: a plain language summary

Immunotherapy
Plain Language Summary What is this summary about? The LILAC study was performed in two separate parts, to see how litifilimab, an antibody, worked for two distinct forms of lupus.
Richard A. Furie, R. V. van Vollenhoven, K. Kalunian, Sandra V Navarra, J. Romero-Díaz, Victoria Werth, Xiaobi Huang, H. Carroll, Adam Meyers, Cristina Musselli, N. Franchimont, Catherine Barbey   +11 more
semanticscholar   +1 more source